MATN Mateon Therapeutics Inc.

MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL

MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL
EN
12/10/2020

Underlying

MATNMateon Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mateon Therapeutics Inc.

 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics and Sapu Bioscience Announce Publication on Sub...

Oncotelic Therapeutics and Sapu Bioscience Announce Publication on Sub-15 nm Nanoparticles in International Journal of Molecular Sciences Breakthrough Review Defines the Next Frontier in Precision Nanomedicine Agoura Hills, CA, and San Diego, CA, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics Inc. (OTLC) and JV partner Sapu Bioscience today announced the publication of their landmark review article, “Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential,” in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842; ) . Authored by...

4h / 36m 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (...

Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) AGOURA HILLS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor microenvironment, announced today that Sapu Nano will be featuring its investigational intravenous Deciparticle™ everolimus (Sapu003) have been accepted fo...

October 30, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (...

Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) Accepted Presentations Showcase First-in-Human Development, Manufacturing Innovation, and Predictive Biomarkers for Deciparticle™ Everolimus (Sapu003) AGOURA HILLS, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor mic...

October 23, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic to Present at the LD Micro Main Event XIX

Oncotelic to Present at the LD Micro Main Event XIX AGOURA HILLS, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor microenvironment, announced today that it will be presenting at the 19th Annual Main Event on Tuesday, October 21, at 11:30 a.m. PT at the Hotel del Coronado in San Diego, California. Vuong Trieu, Ph.D., CEO, will be giving the ...

October 20, 2025 1 EN
 PRESS RELEASE
Free
MATN Mateon Therapeu...

Oncotelic Therapeutics Showcases Robust Pipeline and Founder’s Broad I...

Oncotelic Therapeutics Showcases Robust Pipeline and Founder’s Broad Intellectual Property Contributions to Biopharma Industry Highlighting multibillion-dollar drug discoveries and advancing novel oncology and immunotherapy assets AGOURA HILLS, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“OTLC” or the “Company”), a clinical stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, today highlights the depth of its oncology and immunotherapy pipeline while recognizing the extraordinary intellectual property c...

August 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch